HSBC Holdings’s Axsome Therapeutics AXSM Stock Holding History

HSBC Holdings’s Portfolio AXSM Stock Details AXSM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$11.6M	Buy	+68,453	New	+$11.8M	0.01%	890
2025 Q4	–	Sell	-101,001	Closed	-$12.3M	–	2929
2025 Q3	$12.3M	Buy	101,001 +2,883	+3%	+$325K	0.01%	858
2025 Q2	$10.2M	Buy	98,118 +14,546	+17%	+$1.54M	0.01%	901
2025 Q1	$9.74M	Sell	83,572 -53,213	-39%	-$6.06M	0.01%	905
2024 Q4	$11.6M	Sell	136,785 -279	-0.2%	-$25.7K	0.01%	890
2024 Q3	$12.3M	Buy	137,064 +133,279	+3,521%	+$11.6M	0.01%	862
2024 Q2	$301K	Sell	3,785 -1,051	-22%	-$77.8K	﹤0.01%	2276
2024 Q1	$386K	Sell	4,836 -75,601	-94%	-$6.35M	﹤0.01%	2248
2023 Q4	$6.37M	Sell	80,437 -68,375	-46%	-$4.57M	0.01%	1065
2023 Q3	$10.4M	Buy	+148,812	New	+$11.1M	0.01%	814
2021 Q1	–	Sell	-2,593	Closed	-$211K	–	2733
2020 Q4	$211K	Buy	+2,593	New	+$194K	﹤0.01%	2787
2020 Q1	–	Sell	-2,401	Closed	-$254K	–	2698
2019 Q4	$254K	Buy	+2,401	New	+$97K	﹤0.01%	2678

Other funds holding AXSM

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

HSBC Holdings's AXSM Position: Q1 2026 in Review

HSBC Holdings opened a new position in Axsome Therapeutics (AXSM) in Q1 2026: 68,453 shares worth $11.6M. The stake represents 0.01% of the portfolio and ranks #890 among its holdings. This is a return to the name: HSBC Holdings previously reported a position in AXSM as recently as Q3 2025.

HSBC Holdings first reported a position in AXSM in Q4 2019 and has held it in 12 quarters since. The position peaked at $12.3M in Q3 2024. 409 funds tracked by Wall St. Rank hold AXSM as of Q1 2026.

HSBC Holdings held 68,453 shares of Axsome Therapeutics worth $11.6M as of Q1 2026.
Axsome Therapeutics was a new HSBC Holdings position in Q1 2026.
Axsome Therapeutics made up 0.01% of HSBC Holdings's portfolio in Q1 2026, its #890 holding.
HSBC Holdings first reported a position in Axsome Therapeutics in Q4 2019 and has held it in 12 quarters since.
HSBC Holdings's Axsome Therapeutics position peaked at $12.3M in Q3 2024.
409 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q1 2026.

Based on HSBC Holdings's 13F filing for Q1 2026, filed 30 Apr 2026.